Immune Therapeutics, Inc. cancelled the acquisition of Aletheia Therapeutics, Inc..
December 16, 2020
Share
Immune Therapeutics, Inc. (OTCPK:IMUN) entered into a definitive agreement to acquire Aletheia Therapeutics, Inc. on December 16, 2019. Pursuant to the agreement Immune will acquire all of the outstanding shares of Aletheia in exchange for Immune common stock. In connection with the acquisition, the Aletheia management team will join the leadership of the combined company as well as selected board members of Aletheia. The closing of the offer will be subject to certain conditions, including completing due diligence, the employment of the Aletheia management team to Immune management team and the assignment of all intellectual property to Immune. The acquisition is expected to close early in the first quarter of 2020.
Immune Therapeutics, Inc. (OTCPK:IMUN) cancelled the acquisition of Aletheia Therapeutics, Inc. on December 16, 2020.
Biostax Corp. is a developer and marketer of pharmaceutical, biotechnology, and MedTech products. The Company has partnerships in the fields of autoimmunity and immune restoration and are able to deliver solutions today for people that are living with autoimmunity, chronic inflammation, infection, and cancer. Its internal and partner programs comprised of JKB-122, an investigational small molecule, long-acting toll-like receptor 4 (TLR4) antagonist developed for autoimmune hepatitis, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) that has demonstrated anti-fibrotic, immuno-modulating, and anti-inflammatory activities in preclinical models; Lodonal, is a once-a-day immune system regulator for the management of human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS), and LDN, which is a compound formula that is purported to provide immune-modulating benefits that include cancer, pain, autoimmune, and anti-aging.
BIOSTAX CORP. 
